

Pricing Guidelines for Listed Products and OTC Derivatives Clearing Services offered by UBS

EMIR Articles 38(1) and 39(7), including Commission Delegated Regulation (EU) No 2021/1456 and Markets in Financial Instruments Directive II and Regulation (collectively MiFID II)

1. Introduction

The European Market Infrastructure Regulation (EMIR) of the European Parliament and of the Council of 4 July 2012 on OTC derivatives, central counterparties (CCPs) and trade repositories entered into force on 16 August 2012.

Directive 2014/65/EU of the European Parliament and of the Council on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (recast) entered into force on 15 May 2014.

Regulation (EU) No 600/2014 of the European Parliament and of the Council on markets in financial instruments and amending Regulation (EU) no 648/2012 entered into force on 15 May 2014.

Commission Delegated Regulation (EU) No 2021/1456 supplementing EMIR by specifying the conditions under which the commercial terms for clearing services for OTC derivatives are to be considered to be fair, reasonable, non-discriminatory and transparent (FRANDT), entered into force on 2 June 2021

EMIR Articles 38(1) and 39(7) and MiFID II set out certain information that we are required to provide to you where we clear derivatives for them, either directly or indirectly through an EU central counterparty that has been reauthorized under EMIR (CCP). This document sets out the factors which impact the cost of clearing with, and therefore price/commission revenues which will be charged by, UBS. This document also covers the additional requirement as set out under FRANDT such that they apply only to OTC derivative contracts that are subject to the clearing obligation in accordance with Article 4(1) of Regulation (EU) No 648/2012..

As further described herein, UBS's commission revenues are determined on the basis of (i) an assessment of a client's profitability, (ii) the minimum annual revenue thresholds applied by UBS, (iii) general pricing considerations, (iv) a client's required level of segregation, (v) any additional services provided and (vi) a client's wider relationship with UBS. All of these factors combined with a client's current and future offering are taken into consideration when determining a client's commission structure on a cost per lot basis including the ability to benefit from any discounts or rebates.

UBS's commission revenues are determined excluding any exchange/clearing house/agent broker fees, details of which can be obtained either from the relevant organization directly or from your UBS Sales Representative.



2. Client Profitability

As mentioned above, the commission revenues that UBS will charge a client for providing clearing services is dependent in part on UBS's assessment of that client's profitability. UBS typically measures client profitability using three main profitability indicators return on attributed equity of greater than 20% pre tax, Return on Risk Weighted Assets of 8% or greater and return on LRD of 1.5% or greater.

3. Minimum Revenue Thresholds

In addition to meeting the profitability indicators, UBS also applies minimum revenue thresholds which a client must meet in order to establish and maintain a clearing relationship with UBS. These are currently set at USD 150,000 of commissions per annum for the execution and clearing of Listed Derivatives and clearing of OTC Cleared Derivatives.

4. General Pricing Considerations

As part of the determination of the profitability indicators, the elections made by a client with respect to its clearing offering will be taken into account. The core criteria which impact the cost to UBS of clearing and therefore a client's overall commission structure are set out below. Each factor is considered separately and will have a varying impact on the cost per lot/cost per million notional.

Criteria	Decreases Fees	Increases Fees
Product Type	Listed Derivatives ¹	OTC Cleared Derivatives ²
Traded Exchanges & Products	Mature or STP markets	Bespoke or non STP markets
Execution Method	Direct market access	Voice execution
Execution Wallet	Execution done with UBS	Execution done away
Trading Volumes	High	Low
Contract Settlement	Cash	Physical
Portfolio Risk Attributes	Diversified portfolios Low duration fixed income portfolios (lower LRD footprint, lower RWAs)	Option heavy portfolios (Risk management model / Stress Loss consumption /) Directional and concentrated portfolio
Onboarding Complexity	Low complexity, single account standard offering	High complexity, multiple accounts or bespoke legal terms

¹ This is generally the case but there may be exceptions

² This is generally the case but there may be exceptions



Collateral Type	Non-cash collateral	Cash collateral
Client Credit Rating ³	Moody's, S&P, Fitch Aaa, AAA, AAA	Moody's, S&P, Fitch
Number of Accounts	Low	High
Average Pricing	Straight through processing	Manual
Allocation Process	Pre clearing allocation	Post clearing allocation

5. Additional Costs associated with Segregation

Under EMIR, where we are providing services to you that involve us clearing derivatives through a CCP in the capacity of clearing member, we must offer you at least the choice of omnibus client segregation and individual client segregation, and inform you of the costs and level of protection associated with each option.

Additionally, under EMIR and MiFID II, where we are providing services to you that involve us either providing indirect clearing services as set out in the Indirect Clearing RTS, or clearing derivatives indirectly as a client of a clearing member through a CCP, we must offer you a choice of a basic omnibus indirect client account (BOSA [also referred to as net omnibus account or NOSA]) and a gross omnibus indirect client account (GOSA) and inform you of the costs and level of protection associated with each option.

The cost to clients of different account structures at different CCPs, and the level of protection afforded, vary. Considerations include the risk in the event of default of the clearing member or another client, likelihood of porting, capital requirements for banks and operational complexity. In this regard please note the EMIR disclosure document for the respective UBS entity you are contracting with, which sets out a high level overview of the different levels of protection associated with the different levels of segregation and different CCP clearing offerings.

The cost for clearing on an omnibus basis is determined by way of application of the factors set out above. Opting for individual client segregation or gross omnibus segregation as applicable for all or some of your clearing business with UBS may involve additional charges. These fees are determined based on individual client requirements including, but not limited to; the number of currencies required to be supported, whether positions are held net or gross, base or multi-currency margining and the number of accounts.

For example, indicative charges for a client with one ISA or GOSA using multi-currency margining on up to five currencies, are:

- 1. Monthly account maintenance charge of up to USD 6k per account per CCP4
- 2. Additional bps charge on initial margin posted, dependent on CCP

³ Client Credit Rating is measured by an internal framework which is not disclosed to clients but equates to Moody's, Standard & Poor's and Fitch credit agency scores.

⁴ The monthly account maintenance charge could in certain circumstances be higher, such as for a larger number of currencies.



6. Additional Services

The commissions charged by UBS may increase where a client is offered, (at UBS's discretion) and takes advantage of, the additional services described below:

Reporting and Technology Solutions

UBS pricing is inclusive of access to our standard reporting tool – SwisKey Clearing as well as the distribution of standard reports. Customized reporting requirements may incur additional charges, which will be agreed with the client as part of the onboarding and set up process.

Collateral Management Fees

In addition to the commission fees and considerations detailed above, clients are charged a monthly collateral management fee based on the utilization of non-cash collateral to cover margin requirements, the eligibility of the collateral at the underlying exchange and collateral concentration risks. Fees, acceptable collateral and the respective haircuts are agreed with the client before the go-live and defined in the client commission schedule.

Collateral Transformation

Where a client needs the ability to use collateral margin that is not eligible for onward delivery to an applicable CCP, UBS offers a collateral transformation service. The type of non-eligible collateral, its quality and liquidity will determine the charges applied.

Cash Transformation

Where a client needs the ability to use cash margin that is not in an eligible currency for onward delivery to an applicable CCP, UBS offers a cash transformation service. A credit and debit interest rate with an additional spread will be applied for positive and negative cash balances in each currency. The interest rates are based on prevailing benchmark rates in each currency and are detailed in the client commission schedule.

Backup Clearing Member

Pricing for back up clearing services is considered using the same framework as a primary clearing relationship.

7. Pricing Examples

The following pricing examples have been included in order to give a practical example of the manner in which the above profitability indicators and general pricing considerations are taken into account when determining the commission revenues charged by UBS on a cost per lot/dollar per million notional basis. These represent one possible solution, out of many available, for each product type and are provided for information only on an indicative basis and based on UBS providing clearing services to a Baa1 / BBB / BBB5 rated client.

In these examples, no additional services are being utilized.

⁵ Moody's / S&P / Fitch credit ratings



Cost of clearing Listed Derivatives⁶:

Exchange:	ICE Europe
Product Type:	Bond Future
Average Initial Margin	USD 30m
Average net open position	9,000 lots futures
Anticipated annual volumes:	250,000
Execution cost	USD 0.50 per lot
Clearing cost	USD 0.50 per lot
Omnibus account charge	USD 0.00
Individually Segregated or Gross Omnibus account - account maintenance charge	USD 6,000 per month
Individually Segregated or Gross Omnibus account - funding charge	20 bps

Cost of clearing OTC Cleared Derivatives:

Clearing House	London Clearing House
Product Type:	Interest Rate Swap
Average Initial Margin	USD 20m
Average net open position	450m average gross notional exposure in IRS with 10 years average maturity
Anticipated annual volumes:	50 tickets
Clearing cost	USD 25.00 per mio notional
	100 bps IM charge
Omnibus account charge	USD 0.00
Individually segregated account - account maintenance charge	USD6,000 per month
Individually segregated account - funding charge	20 bps

8. Wider UBS relationship

A client's wider relationship within the UBS Group may be taken into consideration as part of the pricing process.

⁶ Listed Derivatives clearing cost per lot quoted in USD based on a 'Cost Plus' methodology and does not include exchange or clearing house fees



9. Further Information

The disclosure on our pricing guidelines contained herein and the information contained within the <u>EMIR disclosure document</u> have been produced so as to provide prospective and existing clients with a high level overview of the available clearing structures and our pricing and so as to assist client's in making their election as to their preferred account structure, but do not constitute legal or any other form of advice and should not be relied upon as such. The disclosures do not provide all of the information you may need to make your election and it is the client's responsibility to review and conduct their own due diligence on the legal documentation and terms of UBS's clearing offering and relevant rules and structures of the various CCPs. We would encourage clients to contact their UBS Sales representative to discuss UBS's clearing offering in further detail.

Conditions of service including specific contractual terms

Criteria for acceptance of orders

Conditions for suspension of service or the liquidation / close out of positions

Conditions for the termination of the contract



This material has been issued by UBS AG and/or any of its affiliates ("UBS", "our", "we" and "us"). The securities, derivatives or other financial instruments described herein ("Instruments") may not be eligible for sale in all jurisdictions or to certain categories of investors. This material is for distribution only under such circumstances as may be permitted by applicable law, rules and/or regulations. All communications between you and us may be monitored.

Please also see further details as set out under "Country-specific information" below.

Provenance and purpose

This material has been prepared by sales or trading personnel and it is not a product of our Research Department and is not intended to recommend, suggest or inform an investment strategy. Opinions expressed may differ from the opinions expressed by our other divisions, including those of the Research Department.

Recipient to exercise own judgment

The information contained herein should not be regarded by recipients as a substitute for the exercise of their own judgment. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute the provision of investment advice. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisers to the extent you deem necessary to make your own investment, hedging and trading decisions.

Not an offer to transact

This material has been prepared for informational purposes only and is not an offer to buy or sell, or a solicitation of an offer to buy or sell. any Instrument or to participate in any particular trading strategy. This material is not an official confirmation of terms.

Conflicts of Interest

This material may contain proprietary commentary produced in conjunction with our trading desks that trade as principal in the Instruments. This commentary may therefore not be independent from our proprietary interests or those of connected parties which may conflict with your interests. We may have accumulated, or may acquire, a long or short position in the subject Instrument, or related derivative, on the basis of this material prior to its dissemination.

We may trade as principal or otherwise act, or have acted, as market-maker and/or as an execution venue in the Instruments. Instruments may be highly illiquid which may adversely impact the price, spread and speed of execution of orders in those Instruments. Furthermore, we may have, or have had, a relationship with or may provide, or have provided, investment banking, capital markets and/or other financial services to the companies associated with the Instruments.

We have policies and procedures in place which are designed to manage conflicts of interest. In order to control the flow of information contained in an area of UBS we may rely on information barriers. Additional information can be found at: www.ubs.com/ibterms

Contents of Material

This material is prepared from information believed to be reliable, but we make no representations or warranties, express or implied, and owe no duties (including in negligence) as to the accuracy, completeness or reliability of the material, nor is it intended to be a complete statement or summary of the Instruments, markets or developments referred to. The material is subject to change without notice. We do not undertake any obligation to update this material. Any prices or quotations contained herein are indicative only and are not for valuation purposes. Past performance is not necessarily indicative of future results.



Statement of Risk

The Instruments are not suitable for all investors, and trading in these Instruments is considered risky and is appropriate only for sophisticated investors and in particular any target market identified herein. These Instruments may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates, foreign exchange rates and other market conditions. Some Instruments may be physically settled or cash settled.

No Liability

To the fullest extent permitted by law, neither we nor any of our directors, employees or agents is liable for any loss (including indirect, special or consequential losses or damages, even if we have been advised of the possibility of such loss or damage) arising out of any person's use of, or reliance upon, the information contained herein.

Securities Act

Any Instruments that have not been registered under the United States Securities Act of 1933 may not be offered or sold in the United States except under an exception from the registration requirements of the Securities Act and applicable state securities laws.

No redistribution or reproduction

We specifically prohibit the redistribution or reproduction of this material in whole or in part without our prior written permission and we accept no liability whatsoever for the actions of third parties in this respect.

© UBS 2022. All rights reserved.

Country-specific information

Except as otherwise specified herein, these materials are distributed to professional clients only, and are not suitable for retail clients.

For further important country-specific information, please see the following link: www.ubs.com/sales-and-trading-country-information